These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from June 29 through July 5, 2023. Source: VerityData
Activist Holdings
Masimo
(MASI)
Politan Capital disclosed holding an 8.9% interest in the monitoring-technology company of 4,713,518 shares. This makes Politan a top-five shareholder in Masimo, according to S&P Capital IQ. In May, Politan Capital submitted Michelle Brennan and founder Quentin Koffey for election to Masimo’s board at the 2023 annual shareholder meeting on June 26. Both were elected as Masimo directors. Per Politan’s Koffey, the vote is a “mandate from shareholders that significant change is needed.”
Masimo stock has risen about 7% year to date through the close on July 6.
Decreases in Holdings
Vera Therapeutics
(VERA)
Carlyle Group
(ticker: CG) cut its position in the pharmaceutical company to 2,416,837 shares. Carlyle subsidiary Abingworth Bioventures 8 LP sold 543,394 Vera Therapeutics shares at per-share prices ranging from $16.97 to $18.34 from June 27 through June 30. Following those sales, Carlyle owns a 5.5% Vera Therapeutics stake.
The company’s mid-June announcement of positive phase 2b trial results for its Berger disease treatment made Vera Therapeutics stock more than double over the past three months. Even so, the stock sports a year-to-date drop of about 20%.
GMS
(GMS)
Coliseum Capital continued to reduce its interest in the specialty building-products distributor, selling 1.56 million GMS shares in mid-June.
From June 27 through June 29, Coliseum Capital sold 817,670 GMS shares at prices ranging from $70 to $71.68 each. Coliseum Capital now owns 3,417,651 GMS shares, equal to 8.4% of the company’s outstanding stock. That compares to the nearly 6.34 million shares Coliseum owned at the end of September 2022, an almost 14.5% position in GMS at the time.
In late June, GMS reported the fiscal year ended April 30 set record levels of net sales, net income, adjusted earnings before interest, taxes, depreciation, and amortization (Ebitda), and cash-flow generation.
I-Mab
(IMAB)
HHLR Advisors trimmed its holding in the Chinese biopharmaceutical company to 6,909,220 American depositary shares, equal to 15,891,211 ordinary shares. HHLR sold 45,222 I-Mab ADRs on June 28 at a price of $3.03 apiece. As a result, HHLR now owns an 8.3% interest in I-Mab. The stock has lost a little more than a third of its value year-to-date through July 6, the day shares set a record intraday low of $2.61.
Mueller Industries
(MLI)
Gamco Investors
(GBL) reduced its position in the industrial hardware maker to 3,475,947 shares. Gamco Investors sold 326,706 Mueller Industries shares from May 1 through June 28 at prices ranging from $71.48 to $86.75 each, and purchased just 600 shares on May 24 at an average per-share price of $75.14. Following the transactions, Gamco Investors holds 6.1% of Mueller Industries’ tradable stock.
Email: [email protected]
Read the full article here
